Ingredion

Ingredion

Ingredion was founded in 1906 as Corn Products Refining Company by the merger of several starch and glucose producers. James Zallie has served as President and CEO since 2018, steering a publicly traded entity (NYSE: INGR) with roughly $8 billion in annual revenue rather than a traditional family office or fund structure. The original wealth and capital base came from its industrial operations, making it distinct from firms rooted in financial services or technology exits. Ingredion deploys capital directly into its manufacturing network and R&D infrastructure, functioning as a vertically integrated operator rather than a third-party fund manager. The asset base comprises 44 owned or operated facilities concentrated in the Americas and Asia-Pacific, including major plants in the United States, Mexico, Brazil, and Thailand. The firm's investment posture targets bolt-on acquisitions that expand its specialty ingredient portfolio — recent examples include the purchase of KaTech, a European texturizing and stabilization house, and the expansion of its pea protein facility in South Sioux City, Nebraska, to capture plant-based protein demand. The company operates with a global workforce exceeding 10,000 and maintains regional headquarters in São Paulo, Shanghai, and Manchester alongside its central office in Westchester, Illinois. In April 2024, Ingredion completed a significant organizational restructuring, consolidating operations under a new global business model to streamline decision-making and reduce costs. Adjacent vehicles include the Ingredion Foundation, which directs charitable giving toward food security and STEM education in the communities surrounding its plants. Ingredion's structural differentiator is that it does not allocate to external funds or make financial-return-driven LP commitments. It invests solely in its own operating capacity — a permanent capital model where retained earnings finance plant construction, acquisition of competitor technologies, and ingredient innovation. This makes it a corporate investor whose 'deployment' is measured in factory lines and pilot labs rather than fund vintages or IRR targets.